LexisNexis® Legal Newsroom
$8M Fosamax Verdict Remitted By MDL Judge To $1.5M Or New Damages Trial

NEW YORK -- (Mealey's) The New York federal judge overseeing the Fosamax multidistrict litigation on Oct. 4 sua sponte found that an $8 million verdict in a bellwether trial is excessive and ordered a remittitur of the verdict to $1.5 million unless plaintiff Shirley Boles wants a new trial on damages...

Jury Finds For Merck In Bellwether Fosamax Jaw Disease Trial

NEW YORK - (Mealey's) A federal court jury in New York on Nov. 19 found that Merck & Co. Inc.'s osteoporosis drug Fosamax did not cause the osteonecrosis that destroyed a Florida woman's jaw ( Judith Graves v. Merck & Co. Inc. , 1:06-cv-05513, S.D. N.Y.). Seven jurors in the U...

Merck Wins Defense Verdict In 1st Fosamax Femur Case To Go To Verdict

TRENTON, N.J. - (Mealey's) A New Jersey federal jury on April 29 quickly found that Fosamax did not cause a plaintiff's femur fracture, the first verdict in a case in which a plaintiff claims that the osteoporosis drug weakened her thigh bone ( In Re: Fosamax [Alendronate Sodium] Products Liability...

3rd Circuit Says Design Defect Claims For Generic Fosamax Are Preempted

PHILADELPHIA — (Mealey’s) Strict liability design defect claims involving generic versions of the osteoporosis drug Fosamax are preempted by federal law despite plaintiffs’ attempts to narrow U.S. Supreme Court case law, a panel of the Third Circuit U.S. Court of Appeals ruled April...